The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Journal of Endocrinological Investigation · 14.08.2024 · 47 (11) · 2671-2678
DOI: 10.1007/s40618-024-02441-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinological Investigation, online erschienen am 14.08.2024. Verfasst von I Caruso und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Uni…. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration, Pharmacovigilance, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Recovery and Resilience Plan, Investment PE8 – Project Age-It: “Ageing Well in an Ageing Society”., Università degli Studi di Bari Aldo Moro.
Abstract (Originalsprache)
Purpose
Randomized controlled trials with tirzepatide (TZP) displayed unprecedented glucose and body weight lowering efficacy in individuals with type 2 diabetes and/or obesity and a safety profile similar to that of glucagon-like peptide-1 receptor agonists (GLP-1RA), mainly characterized by gastrointestinal (GI) adverse events (AE). Concerns on diabetic retinopathy, pancreato-biliary disorders, and medullary thyroid cancer were also addressed. We aimed to investigate whether the same safety issues emerged from the FDA Adverse Event Reporting System (FAERS) post-marketing surveillance database.
Methods
OpenVigil 2.1-MedDRA-v24 and AERS Mine (data 2004Q1-2023Q3) were used to query the FAERS database. Reports of GI AE, diabetic retinopathy, pancreato-biliary disorders, and medullary thyroid cancer were investigated. The analysis was then filtered for age, gender, and designation as primary suspect. AE occurrence with TZP was compared to insulin, sodium-glucose cotransporter-2 inhibitors, metformin, and GLP-1RA.
Results
Disproportionate reporting of GI [i.e., nausea (ROR 4.01, 95% CI 3.85–4.19)] and pancreato-biliary disorders [i.e., pancreatitis (ROR 3.63, 95% CI 3.15–4.19)], diabetic retinopathy (ROR 4.14, 95% CI 2.34–7.30), and medullary thyroid cancer (ROR 13.67, 95% CI 4.35–42.96) was detected. TZP exhibited a similar risk of GI AE and medullary thyroid cancer and a lower risk of most pancreato-biliary AE and diabetic retinopathy vs. GLP-1RA.
Conclusions
TZP was associated with an increased risk of specific AE. However, its safety profile was similar to that of GLP-1RA, without increased risk of pancreato-biliary AE, diabetic retinopathy, and medullary thyroid cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
- Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy. francesco.giorgino@uniba.it.
Förderung
- National Recovery and Resilience Plan, Investment PE8 – Project Age-It: “Ageing Well in an Ageing Society”.
- Università degli Studi di Bari Aldo Moro
Zitieren
APA
Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., & Giorgino, F. (2024). The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Journal of Endocrinological Investigation, 47(11), 2671-2678. https://doi.org/10.1007/s40618-024-02441-z
Vancouver
Caruso I, Di Gioia L, Di Molfetta S, Caporusso M, Cignarelli A, Sorice GP, et al. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Journal of Endocrinological Investigation. 2024;47(11):2671-2678. doi:10.1007/s40618-024-02441-z
BibTeX
@article{Caruso2024,
author = {Caruso, I and Di Gioia, L and Di Molfetta, S and Caporusso, M and Cignarelli, A and Sorice, G P and Laviola, L and Giorgino, F},
title = {The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database},
journal = {Journal of Endocrinological Investigation},
year = {2024},
volume = {47},
number = {11},
pages = {2671--2678},
doi = {10.1007/s40618-024-02441-z}
}
EUVIMED